西地尼布联合顺铂和培美曲塞治疗初治不可切除恶性胸膜间皮瘤的I期试验(SWOG S0905)
SWOG S0905是一项I期剂量递减试验,将西地尼布(30 mg和20 mg每日两个剂量队列)联合顺铂-培美曲塞用于初治不可切除恶性胸膜间皮瘤患者,共入组20例。30 mg队列初始6例中2例出现剂量限制性毒性,该剂量被认为毒性过大而停止;20 mg队列中2例出现剂量限制性毒性,确定最大耐受剂量为西地尼布20 mg。结论认为该三药方案毒性谱合理且初步疗效有前景。
要点
- 西地尼布30 mg队列初始6例中2例出现剂量限制性毒性,该剂量被认为毒性过大。
- 20 mg队列中2例出现剂量限制性毒性,确定西地尼布最大耐受剂量为20 mg。
- 20 mg联合治疗期间出现3级中性粒细胞减少和胃肠道毒性及4级血小板减少,无患者发生显著出血事件。
核心结论
- 西地尼布联合顺铂-培美曲塞具有合理的毒性谱和初步有前景的疗效。
- II期S0905试验将评估该三药方案对比当前标准治疗顺铂-培美曲塞的疗效。
研究设计与样本
- S0905是一项I期试验,采用剂量递减方案,将西地尼布(30 mg和20 mg每日两个剂量队列)联合顺铂-培美曲塞治疗6个周期,随后西地尼布维持治疗。
- 研究对象为任何组织学亚型的初治不可切除恶性胸膜间皮瘤患者。
- 主要终点为在剂量递减方案中确定西地尼布联合顺铂-培美曲塞的最大耐受剂量。
- 共入组20例患者,其中30 mg队列7例,20 mg队列13例。
主要发现
- 西地尼布30 mg队列初始6例患者中2例报告剂量限制性毒性,该剂量被认为毒性过大而停止继续。
- 下一队列中2例患者出现剂量限制性毒性,因此确定西地尼布最大耐受剂量为20 mg。
- 在顺铂-培美曲塞-西地尼布20 mg联合治疗6个周期期间,出现3级毒性(中性粒细胞减少和胃肠道毒性)和4级血小板减少。
- 无患者发生任何显著出血事件。
- 根据实体瘤疗效评价标准(可评估17例),中位无进展生存期为12.8个月(95%CI:6.9-17.2)。
关键数值与推荐
- 西地尼布最大耐受剂量确定为20 mg每日。
- 根据实体瘤疗效评价标准(可评估17例),中位无进展生存期为12.8个月(95%CI:6.9-17.2)。
- 根据改良实体瘤疗效评价标准(可评估19例),中位无进展生存期为8.6个月(95%CI:6.1-10.9)。
- 全部患者6周时疾病控制率为90%,中位总生存时间为16.2个月(95%CI:10.5-28.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In malignant pleural mesothelioma, targeting angiogenesis with cediranib, a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, may have therapeutic potential. METHODS: S0905 phase I combined cediranib (two dose cohorts [30 mg and 20 mg daily]) with cisplatin-pemetrexed for six cycles followed by maintenance cediranib in unresectable chemonaive patients with malignant pleural mesothelioma of any histologic subtype. The primary end point established the maximum tolerated dose in combination with cisplatin-pemetrexed in a dose deescalation scheme. RESULTS: A total of 20 patients were enrolled (seven to the 30-mg cohort and 13 to the 20-mag cohort). In the cediranib 30-mg cohort, two of the initial six patients reported dose-limiting toxicities and the dose was deemed too toxic to continue. In the next cohort, two patients experienced dose-limiting toxicities, and thus, the maximum tolerated dose of cediranib was established as 20 mg. During the six cycles of cisplatin-pemetrexed-cediranib, 20 mg, there were grade 3 toxicities (neutropenia and gastrointestinal) and grade 4 thrombocytopenia. No patients had any significant episodes of bleeding. According to the Response Evaluation Criteria in Solid Tumors (n = 17 evaluable patients), the median progression-free survival was 12.8 months (95% confidence interval [CI]: 6.9-17.2); according to the Modified Response Evaluation Criteria in Solid Tumors (n = 19 evaluable patients), the median progression-free survival was 8.6 months (95% CI: 6.1-10.9). For all patients, the disease control rate at 6 weeks was 90% and median overall survival time was 16.2 months (95% CI: 10.5-28.7). CONCLUSIONS: Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy. The phase II S0905 trial will evaluate the efficacy of the triplet regimen compared with the current standard of care, cisplatin-pemetrexed.
引用
- Tsao AS, Moon J, Wistuba II, et al. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol. 2017. PMID: 28599887. doi:10.1016/j.jtho.2017.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。